76 terminated. 76 Phase 2, 12 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 76 | Terminated 76 |
| Phase 3 | 12 | Terminated 12 |
| Phase 1 | 3 | Terminated 3 |
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD) Lemborexant, Placebo - Major Depressive Disorder(MDD), Insomnia Comorbid to Psychiatric Disorder | Phase 2 | Terminated | Unity Health Toronto | 30 | 2024-09-25 | 2026-07-30 |
| SAINT for MDD in an Inpatient Setting Follow-on Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| BHV-7000 Open-Label Extension Bipolar Mania Study BHV-7000 - Bipolar Disorder | Phase 2 | Terminated | Biohaven Therapeutics Ltd. | 94 | 2024-06-24 | 2025-12-16 |
| Phase 2 Clinical Trial of GH001 in Bipolar II Disorder GH001 - Bipolar II Disorder | Phase 2 | Terminated | GH Research Ireland Limited | 6 | 2023-04-06 | 2025-02-18 |
| Phase 2 Clinical Trial of GH001 in Postpartum Depression GH001 - Postpartum Depression, Postnatal Depression | Phase 2 | Terminated | GH Research Ireland Limited | 10 | 2023-03-02 | 2025-02-18 |
| KAP for Depression in Abstinent Opioid Users Ketamine-assisted psychotherapy - Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission | Phase 2 | Terminated | Medical University of South Carolina | 5 | 2022-01-13 | 2024-05-06 |
| Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent MIJ821 Intravenous Injection, Placebo Intravenous Injection - Major Depressive Disorder With Suicidal Ideation With Intent | Phase 2 | Terminated | Novartis Pharmaceuticals | 199 | 2021-07-20 | 2026-05-18 |
| Antidepressant Effects of TS-161 in Treatment-Resistant Depression Placebo, TS-161 - Major Depressive Disorder, Treatment-Resistant Depression | Phase 2 | Terminated | National Institute of Mental Health (NIMH) | 11 | 2021-06-10 | 2025-06-10 |
| Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) MK-1942, Placebo - Treatment Resistant Depression | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 99 | 2021-05-20 | 2026-05-04 |
| Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) AXS-05 (dextromethorphan-bupropion) - Treatment Resistant Depression, Major Depressive Disorder | Phase 2 | Terminated | Axsome Therapeutics, Inc. | 181 | 2020-09-23 | 2026-01-28 |
| A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression BI 1358894, Placebo - Depressive Disorder, Major | Phase 2 | Terminated | Boehringer Ingelheim | 45 | 2020-06-22 | 2023-06-13 |
| Biomarkers of Response to Treatment With Frontal Cortex Stimulation for Anxious Depression transcranial direct current stimulation using a Soterix mini-CT device - Major Depressive Disorder, Anxiety | Phase 1 / Phase 2 | Terminated | Mclean Hospital | 1 | 2020-02-13 | 2021-02-12 |
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy Ketamine infusion, Midazolam infusion - Major Depressive Disorder | Phase 2 / Phase 3 | Terminated | Yale University | 3 | 2019-07-17 | 2023-04-24 |
| Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression Ketamine 0.5 mg/kg, Ketamine 0.2 mg/kg - Post Partum Depression | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 1 | 2019-03-04 | 2021-10-19 |
| Salicylic Augmentation in Depression Aspirin 325mg, Placebo Oral Tablet - Depression, Depressive Disorder | Phase 2 | Terminated | Jessica Harder | 32 | 2018-11-15 | 2024-01-31 |
| Fecal Microbiota Transplantation in Depression Fecal microbiota capsules, Placebo oral capsule - Major Depressive Disorder | Phase 2 | Terminated | Psychiatric Hospital of the University of Basel | 4 | 2018-10-24 | 2020-04-16 |
| A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder Rapastinel, Placebo - Depressive Disorder, Major | Phase 2 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 138 | 2017-12-15 | 2020-08-14 |
| Cannabidiol as an Adjunctive Treatment for Bipolar Depression Cannabidiol, Placebo - Bipolar Disorder, Bipolar Depression | Phase 2 / Phase 3 | Terminated | Hospital de Clinicas de Porto Alegre | 36 | 2017-11-01 | 2021-07-02 |
| A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder TS-121 10 mg, TS-121 50 mg, Placebo - Major Depressive Disorder | Phase 2 | Terminated | Taisho Pharmaceutical R&D Inc. | 51 | 2017-07-03 | 2020-07-14 |
Showing 20 of 76. Sign in to see all of them.
Depressive Disorder, Major (48) · Depression (36) · Bipolar Disorder (21) · Depressive Disorder (9) · Depressive Disorder, Treatment-Resistant (8) · Depression, Postpartum (5) · Mania (4) · Suicidal Ideation (3) · Anxiety Disorders (2) · Recurrence (2) · Self-Injurious Behavior (2) · Suicide (2) · Alcoholism (1) · Anemia, Iron-Deficiency (1)
Mental Disorders (75) · Depressive Disorder (50) · Behavior (38) · Behavioral Symptoms (38) · Bipolar and Related Disorders (21) · Pathological Conditions, Signs and Symptoms (9) · Nervous System Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (5) · Neurobehavioral Manifestations (5) · Neurologic Manifestations (5) · Pregnancy Complications (5) · Signs and Symptoms (5) · Urogenital Diseases (5) · Pathologic Processes (4)
Ketamine (6) · Escitalopram (3) · Quetiapine Fumarate (3) · Riluzole (3) · Duloxetine Hydrochloride (2) · Exercise (2) · GLYX-13 peptide (2) · Methoxydimethyltryptamines (2) · Sertraline (2) · orvepitant (2) · 1,2-benzisothiazol-3(2H)-one, 2-(4-(4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl)butyl)-, 1,1-dioxide (1) · 1-(benzofurazan-5-ylcarbonyl)piperidine (1) · 1-phenyl-3,3-dimethyltriazene (1) · AZD2066 (1) · Antidepressive Agents (1)
National Institute of Mental Health (NIMH) (8) · Janssen Research & Development, LLC (4) · AstraZeneca (3) · GlaxoSmithKline (3) · H. Lundbeck A/S (3) · Massachusetts General Hospital (3) · Brigham and Women's Hospital (2) · GH Research Ireland Limited (2) · Magnus Medical (2) · Markus KOSEL (2) · Merck Sharp & Dohme LLC (2) · Naurex, Inc, an affiliate of Allergan plc (2) · Pfizer (2) · Sunnybrook Health Sciences Centre (2) · The University of Texas Health Science Center, Houston (2)
United States (54) · Canada (10) · Netherlands (5) · Germany (4) · Belgium (3) · Russia (3) · Spain (3) · Switzerland (3) · United Kingdom (3) · Brazil (2) · Estonia (2) · France (2) · India (2) · Japan (2) · Malaysia (2)
Carlos A Zarate, M.D. (3) · Jessica Harder, MD (3) · Benjamin I Goldstein, MD (2) · Brandon Bentzley, MD (2) · Jenna Hoogerheyde (2) · Markus Kosel, MD-PhD (2) · Roy H Perlis, MD, MSc (2) · Albert J Arias, MD (1) · Anna R. Brandon, PhD, MSCS (1)
PMID 18413705, PMID 18671864, PMID 20074703, PMID 21199966, PMID 22050051, PMID 23364679, PMID 25422883, PMID 27366831, PMID 28338546, PMID 28582570, PMID 30184133, PMID 31307859, PMID 32637725, PMID 34787653, PMID 35092868, PMID 36375174, PMID 36579458, PMID 37920963, PMID 39715042, PMID 41854661, PMID 42247279
2008 (1), 2017 (1), 271201100006I-0-27100007-1 (1), K23AA017689 (1), R01MH125160 (1)